Immunic (NASDAQ:IMUX) Rating Lowered to “Strong Sell” at Wall Street Zen

Immunic (NASDAQ:IMUX) was downgraded by stock analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report issued on Saturday, Wall Street Zen reports.

Several other analysts have also recently commented on the company. Zacks Research cut Immunic from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunic in a report on Wednesday, August 26th. Wedbush reissued an “outperform” rating and issued a $45.00 target price on shares of Immunic in a research report on Thursday, September 10th. Ladenburg Thalmann & Co. Inc. upgraded shares of Immunic to a “strong-buy” rating in a report on Wednesday, July 29th. Finally, HC Wainwright restated a “buy” rating and issued a $22.00 target price on shares of Immunic in a report on Thursday, September 10th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $35.43.

Immunic Stock Performance

IMUX stock opened at $7.52 on Friday. Immunic has a 52-week low of $5.06 and a 52-week high of $17.43. The stock’s fifty day simple moving average is $8.70 and its 200-day simple moving average is $11.52.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings data on Friday, November 13th. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20). Equities research analysts predict that Immunic will post -3.69 EPS for the current fiscal year.

Institutional Investors Weigh In On Immunic

Several institutional investors and hedge funds have recently added to or reduced their stakes in IMUX. China Universal Asset Management Co. Ltd. grew its holdings in shares of Immunic by 21.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,800 shares of the company’s stock worth $69,000 after purchasing an additional 1,400 shares during the period. Alps Advisors Inc. lifted its position in Immunic by 28.0% during the third quarter. Alps Advisors Inc. now owns 17,694 shares of the company’s stock valued at $165,000 after buying an additional 3,870 shares in the last quarter. CTC Alternative Strategies Ltd. acquired a new position in Immunic during the first quarter valued at approximately $27,000. ADAR1 Capital Management LLC purchased a new stake in Immunic during the first quarter worth approximately $33,000. Finally, State Street Corp grew its stake in Immunic by 36.9% during the third quarter. State Street Corp now owns 83,859 shares of the company’s stock worth $780,000 after buying an additional 22,600 shares during the period. 51.82% of the stock is currently owned by institutional investors and hedge funds.

Latest Immunic News

Investors following IMUX have been watching these news items:

• Positive Sentiment: The company said its pivotal ENSURE-1 and ENSURE-2 trials remain on track to report top-line results in December. It also expects its funding to last into late 2027, giving it runway beyond the upcoming readout. Article: Immunic on track for December Phase 3 readout in relapsing MS, funded into late 2027
• Negative Sentiment: Third-quarter results showed a $42.3 million net loss, with a loss of $0.99 per share—worse than the $0.79 loss analysts expected. Coverage cited higher expenses and the earnings miss as reasons for investor concern. Article: Immunic Q3 loss widens on higher expenses
• Negative Sentiment: Zacks Research downgraded Immunic from “strong-buy” to “hold,” adding to near-term caution ahead of the trial results. Article: Zacks Research stock recommendations

About Immunic

Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule treatments for chronic inflammatory and autoimmune diseases. The company’s research focuses on therapies intended to address conditions with significant unmet medical needs. Its lead drug candidate, vidofludimus calcium, is being developed for multiple sclerosis. Immunic is also advancing other investigational compounds, including IMU-856, which is being studied for its potential to support intestinal barrier function in gastrointestinal diseases.